Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TAK vs NBIX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NBIX Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)

NBIX Overall Winner 6-Pillar Tally: TAK 3 – 3 NBIX Matrix Metrics: TAK 5 – 5 NBIX

As of Nov 16, 2026, Neurocrine Biosciences Inc (NBIX) is the stronger overall head-to-head candidate over Takeda Pharmaceutical Company Limited (TAK) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas NBIX carries 31.4/100 (SELL) at $165.34 (13.6x Forward P/E, 26.6% operating margin).

  • Composite vs. Pillar Nuance: While TAK currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. NBIX 31.4/100 SELL), NBIX captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (26.6% vs. 16.6% operating margin) and revenue trajectory (+41.2% vs. +6.7% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TAK vs NBIX
TAK NYSE
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
TTM Revenue $25.7B
Forward P/E 12.7x
Beta / 30D Vol -0.02β · 22% Vol
Unified Composite Score
47.7 / 100 HOLD
Tech 42.0 Fund 43.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 73
RSI-14: 73.1 · SMA20: $20.72 · SMA50: $19.46
NBIX NASDAQ Head-to-Head Winner
Neurocrine Biosciences Inc
Biological Products, (No Disgnostic Substances)
$165.34
-1.23% 1D
Market Cap $17.1B
TTM Revenue $3.70B
Forward P/E 13.6x
Beta / 30D Vol 0.60β · 54% Vol
Unified Composite Score
31.4 / 100 SELL
Tech 50.0 Fund 36.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 65
RSI-14: 64.7 · SMA20: $155.84 · SMA50: $148.82

6-Pillar Scorecard Institutional Category Breakdown (TAK 3 – 3 NBIX)

Columns: Metric · TAK · NBIX
1. Valuation Multiples TAK
Forward P/E 12.7x 13.6x
Trailing P/E N/M 25.1x
PEG Ratio 0.47x 0.34x
EV / Revenue 2.6x 4.6x
2. Growth & Scale NBIX
Revenue Growth (YoY) +6.7% +41.2%
Earnings Growth (YoY) -9.8% -3.9%
TTM Revenue (USD) $25.7B $3.70B
Market Cap $67.5B $17.1B
3. Profitability & Quality NBIX
Gross Margin 64.8% 64.7%
Operating Margin 16.6% 26.6%
Net Profit Margin 0.9% 19.0%
Return on Equity (ROE) 0.6% 20.4%
4. Balance Sheet & Cash Flow TAK
Cash Generation (TTM) $7.48B EBITDA $1.04B
Cash Flow Margin 29.1% EBITDA Mgn 28.1%
Net Cash / Leverage $14.68 Book/Sh · 0.6% ROE $249M Net Cash
Dividend Yield 2.92% None (0.00%)
5. Options & Positioning NBIX
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 22.4% (5th %ile) 32.0% (22nd %ile)
Put/Call OI Skew Thin ADR Chain 0.24x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat TAK
OpEx & R&D Intensity 48.2% of Rev ($12.4B) 38.1% of Rev ($1.41B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TAK (5) vs NBIX (5)
Institutional Metric TAK NBIX Criterion Row Edge
Market Capitalization
Scale
$67.5B $17.1B Larger Scale TAK
Trailing P/E Ratio
Valuation
N/M 25.1x Lower Multiple NBIX
Forward P/E Ratio
Valuation
12.7x 13.6x Lower Multiple TAK
Revenue Growth (YoY)
Growth
+6.7% +41.2% Higher Growth NBIX
Operating Margin (TTM)
Profitability
16.6% 26.6% Higher Margin NBIX
Net Profit Margin
Profitability
0.9% 19.0% Higher Margin NBIX
Return on Equity (ROE)
Capital Efficiency
0.6% 20.4% Higher ROE NBIX
52-Week Range Position
Momentum
97% ($14–$22) 68% ($122–$186) Stronger Trend TAK
Beta / 30D Volatility
Risk Regime
-0.02β · 22% Vol 0.60β · 54% Vol Lower Realized Risk TAK
Unified Institutional Score
Composite Signal
47.7 / 100 (HOLD) 31.4 / 100 (SELL) Higher Composite TAK
Trailing 12M Revenue (USD)
Operating Scale
$25.7B $3.70B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.8% 64.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.47x PEG · 2.6x EV/Rev 0.34x PEG · 4.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$7.48B EBITDA ($14.68 Book/Sh · 0.6% ROE) $1.04B ($249M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NBIX +11.95 pp
TAK: +9.89% · NBIX: +21.84%
3M Horizon TAK +12.54 pp
TAK: +19.75% · NBIX: +7.21%
6M Horizon TAK +25.28 pp
TAK: +30.45% · NBIX: +5.17%
1Y Horizon TAK +37.1 pp
TAK: +51.79% · NBIX: +14.69%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs NBIX. Trailing 12-month operating profitability (TAK 16.6% vs NBIX 26.6%) and valuation multiples (TAK 12.7x vs NBIX 13.6x Forward P/E) are benchmarked directly in Pillar 4 below.

TAK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$25.7B
Gross Margin64.8%
Op. Margin16.6%
ROE / Fwd P/E0.6% · 12.7x
NBIX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.70B
Gross Margin64.7%
Op. Margin26.6%
ROE / Fwd P/E20.4% · 13.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.4%
IV Percentile 5th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NBIX CONSOLIDATION
91d in phase · OBV ACCUMULATION
Current IV 32.0%
IV Percentile 22nd %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact NBIX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TAK Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment 48.2% of Rev ($12.4B)
90D Engineering Disclosures 0 Published
NBIX Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $17.1B market capitalization and 26.6% operating margin.
OpEx & R&D Reinvestment 38.1% of Rev ($1.41B)
90D Engineering Disclosures 0 Published

Investor FAQ TAK vs NBIX Key Questions & Quantitative Answers

As of Nov 16, 2026, Neurocrine Biosciences Inc (NBIX) is the stronger overall head-to-head candidate over Takeda Pharmaceutical Company Limited (TAK) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas NBIX carries 31.4/100 (SELL) at $165.34 (13.6x Forward P/E, 26.6% operating margin). Composite vs. Pillar Nuance: While TAK currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. NBIX 31.4/100 SELL), NBIX captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (26.6% vs. 16.6% operating margin) and revenue trajectory (+41.2% vs. +6.7% YoY).

NBIX leads the Growth & Scale pillar: TAK posts +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin), compared with NBIX at +41.2% YoY revenue growth and -3.9% YoY earnings growth on $3.70B TTM revenue (64.7% gross margin, 26.6% operating margin). On trailing 12-month operating scale, TAK generates $25.7B in USD-normalized revenue versus $3.70B for NBIX. In operating R&D and SG&A reinvestment, TAK deploys 48.2% of Rev ($12.4B) (0 90-day corporate R&D disclosures) versus 38.1% of Rev ($1.41B) (0 disclosures) for NBIX.

TAK screens cheaper on headline valuation multiples. TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin), whereas NBIX trades at 13.6x Forward P/E, 25.1x Trailing P/E, 0.34x PEG, and 4.6x EV/Revenue (28.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TAK (0.6% ROE) versus NBIX (20.4% ROE) capital efficiency.

In options market volatility and institutional positioning, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk). By comparison, NBIX carries 32.0% implied volatility (22nd %ile, Compressed (<25th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.60β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.